Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration

Bone Marrow Transplantation

Volumn 47, Issue 8, 2012, Pages 1051-1055

  Horwitz, M E ^a   Chute, J P ^a   Gasparetto, C ^a   Long, G D ^a   McDonald, C ^a   Morris, A ^a   Rizzieri, D A ^a   Sullivan, K M ^a   Chao, N J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

G CSF; mobilization; plerixafor; preemptive; stem cell

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; PLERIXAFOR;

ADULT; AGED; APHERESIS; CD34 SELECTION; CELL YIELD; CELLULAR PARAMETERS; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; ENGRAFTMENT; EVENING DOSAGE; FEMALE; GRAFT FAILURE; HEMATOPOIETIC STEM CELL; HUMAN; HYPERLEUKOCYTOSIS; LEUKOCYTE DISORDER; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OBSERVATIONAL STUDY; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; STEM CELL MOBILIZATION;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84864874252     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.217     Document Type: Review

References (17)

1. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin0s lymphoma. J Clin Oncol 2009; 27: 4767-4773.
2. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
3. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Wingard JR et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815-820. (Pubitemid 36410987)
4. Kuittinen T, Nousiainen T, Halonen P, Mahlamaki E, Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin0s lymphoma. Bone Marrow Transplant 2004; 33: 907-912. (Pubitemid 38660123)
5. Akhtar S, Weshi AE, Rahal M, Khafaga Y, Tbakhi A, Humaidan H et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008; 49: 769-778. (Pubitemid 351517224)
6. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-1318. (Pubitemid 40629073)
7. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002; 527: 255-262. (Pubitemid 35253875)
8. Rosenkilde MM, Gerlach LO, Hatse S, Skerlj RT, Schols D, Bridger GJ et al. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem 2007; 282: 27354-27365. (Pubitemid 47501954)
9. Stroncek DF, Clay ME, Herr G, Smith J, Jaszcz WB, Ilstrup S et al. The kinetics of GCSF mobilization of CD34+ cells in healthy people. Transfus Med 1997; 7: 19-24. (Pubitemid 27141041)
10. Grigg AP, Roberts AW, Raunow H, Houghton S, Layton JE, Boyd AW et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-4445.
11. Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G et al. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colonystimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009; 15: 1578-1586.
12. Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, Macpherson J, Winkler K et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2010; 17: 729-736.
13. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64-69.
14. Basak GW, Mikala G, Koristek Z, Jaksic O, Basic-Kinda S, Cegledi A et al. Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late. Leuk Lymphoma 2011; 52: 1711-1719.
15. Duong HK, Bolwell BJ, Rybicki L, Koo A, Hsi ED, Figueroa P et al. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield. J Clin Apheresis 2011; 26: 111-115.
16. Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ et al. Effectiveness and cost analysis of ''just-in-time'' salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011; 51: 2175-2182.
17. Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and cost-benefit analysis of riskadaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion (e-pub ahead of print 11 June 2011; doi:10.1111/ j.1537-2995.2011.03206.x).